Compare Stocks: ARTV, MAZE, RARE, and KARD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$6.99 -6.7%	$10.44	$2.71 ▼ $14.53	$341.74M	2.18	439,757 shs	507,050 shs
KARD Kardigan	$14.79 +2.8%	$19.94	$13.75 ▼ $27.00	$1.38B	N/A	781,553 shs	628,912 shs
MAZE Maze Therapeutics	$26.05 -0.6%	$27.12	$21.95 ▼ $53.65	$1.45B	2.17	755,571 shs	925,607 shs
RARE Ultragenyx Pharmaceutical	$14.50 -1.8%	$22.24	$12.73 ▼ $39.89	$1.43B	0.31	6.68 million shs	4.30 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	0.00%	-18.82%	-41.46%	-27.34%	+142.71%
KARD Kardigan	0.00%	-11.12%	-28.89%	-37.17%	+1,478,999,900.00%
MAZE Maze Therapeutics	0.00%	+15.67%	-8.92%	-8.37%	-0.50%
RARE Ultragenyx Pharmaceutical	0.00%	-0.07%	-44.78%	-52.88%	-49.58%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$6.99 -6.7%	$10.44	$2.71 ▼ $14.53	$341.74M	2.18	439,757 shs	507,050 shs
KARD Kardigan	$14.79 +2.8%	$19.94	$13.75 ▼ $27.00	$1.38B	N/A	781,553 shs	628,912 shs
MAZE Maze Therapeutics	$26.05 -0.6%	$27.12	$21.95 ▼ $53.65	$1.45B	2.17	755,571 shs	925,607 shs
RARE Ultragenyx Pharmaceutical	$14.50 -1.8%	$22.24	$12.73 ▼ $39.89	$1.43B	0.31	6.68 million shs	4.30 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	0.00%	-18.82%	-41.46%	-27.34%	+142.71%
KARD Kardigan	0.00%	-11.12%	-28.89%	-37.17%	+1,478,999,900.00%
MAZE Maze Therapeutics	0.00%	+15.67%	-8.92%	-8.37%	-0.50%
RARE Ultragenyx Pharmaceutical	0.00%	-0.07%	-44.78%	-52.88%	-49.58%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	2.83	Moderate Buy	$39.00	457.94% Upside
KARD Kardigan	2.50	Moderate Buy	$42.25	185.67% Upside
MAZE Maze Therapeutics	3.08	Buy	$63.40	143.38% Upside
RARE Ultragenyx Pharmaceutical	2.48	Hold	$34.58	138.48% Upside

Current Analyst Ratings Breakdown

Latest ARTV, MAZE, RARE, and KARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	MAZE Maze Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/23/2026	MAZE Maze Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$48.00
9/22/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
9/21/2026	MAZE Maze Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	RARE Ultragenyx Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$32.00 ➝ $35.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$18.00 ➝ $20.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $32.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $39.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$33.00 ➝ $39.00

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	$4.48 per share	N/A
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	$20M	72.35	N/A	N/A	$7.38 per share	3.53
RARE Ultragenyx Pharmaceutical	$673M	2.12	N/A	N/A	($0.83) per share	-17.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$83.86M	-$3.30	N/A	N/A	N/A	N/A	-53.86%	-48.16%	11/11/2026 (Estimated)
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-44.40%	11/3/2026 (Estimated)

Latest ARTV, MAZE, RARE, and KARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	KARD Kardigan	N/A	-$4.61	N/A	-$4.61	N/A	N/A
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/6/2026	Q2 2026	ARTV Artiva Biotherapeutics	-$0.6251	-$0.63	-$0.0049	-$0.63	N/A	N/A
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
KARD Kardigan	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	24.16	24.16
KARD Kardigan	N/A	N/A	N/A
MAZE Maze Therapeutics	0.09	18.31	18.31
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
KARD Kardigan	N/A
MAZE Maze Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	1.80%
KARD Kardigan	N/A
MAZE Maze Therapeutics	5.30%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	115	48.89 million	48.01 million	N/A
KARD Kardigan	241	93.50 million	N/A	N/A
MAZE Maze Therapeutics	141	55.55 million	52.61 million	N/A
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable

ARTV, MAZE, RARE, and KARD Headlines

Recent News About These Companies

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Hold" from Brokerages

September 26 at 4:31 AM | americanbankingnews.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts

September 26 at 4:28 AM | marketbeat.com

A Hedge Fund Rolls the Dice on Ultragenyx

September 24 at 11:52 PM | lawstreetmedia.comL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

September 24 at 5:34 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

September 22, 2026 | globenewswire.com

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

September 22, 2026 | finance.yahoo.com

FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?

September 22, 2026 | insidermonkey.com

Bank of America Corp DE Invests $38.35 Million in Ultragenyx Pharmaceutical Inc. $RARE

September 22, 2026 | marketbeat.com

Ultragenyx Pharmaceutical stock gains after FDA approval and fresh analyst targets

September 21, 2026 | ad-hoc-news.deA

Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $35.00 Price Target at Barclays

September 21, 2026 | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Barclays Analyst Says

September 21, 2026 | marketbeat.com

Comparing Anixa Biosciences (NASDAQ:ANIX) and Ultragenyx Pharmaceutical (NASDAQ:RARE)

September 21, 2026 | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

September 20, 2026 | americanbankingnews.com

Canaccord Genuity Group Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

September 20, 2026 | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Citigroup Analyst Says

September 20, 2026 | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Strong Trading Volume Following Analyst Upgrade

September 20, 2026 | americanbankingnews.com

Leerink Partners Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

September 19, 2026 | theglobeandmail.com

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Canaccord Genuity

September 19, 2026 | theglobeandmail.com

How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI

September 19, 2026 | finance.yahoo.com

Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVI™ to Treat ...

September 18, 2026 | newswise.comN

Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo

September 18, 2026 | medcitynews.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARTV, MAZE, RARE, and KARD Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$6.99 -0.50 (-6.68%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$6.98 0.00 (-0.07%)

As of 09/25/2026 07:30 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Kardigan NASDAQ:KARD

$14.79 +0.40 (+2.78%)

As of 09/25/2026 04:00 PM Eastern

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.

Maze Therapeutics NASDAQ:MAZE

$26.05 -0.16 (-0.61%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$26.10 +0.05 (+0.19%)

As of 09/25/2026 07:30 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$14.50 -0.27 (-1.83%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$14.42 -0.08 (-0.55%)

As of 09/25/2026 07:52 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTV, MAZE, RARE, and KARD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTV, MAZE, RARE, and KARD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTV, MAZE, RARE, and KARD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARTV, MAZE, RARE, and KARD Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Kardigan NASDAQ:KARD

Maze Therapeutics NASDAQ:MAZE

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTV, MAZE, RARE, and KARD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTV, MAZE, RARE, and KARD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTV, MAZE, RARE, and KARD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARTV, MAZE, RARE, and KARD Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Kardigan NASDAQ:KARD

Maze Therapeutics NASDAQ:MAZE

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools